Harbor Capital Advisors Inc. Has $3.11 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Harbor Capital Advisors Inc. increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 73.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 168,506 shares of the biotechnology company’s stock after buying an additional 71,372 shares during the period. Harbor Capital Advisors Inc. owned 0.19% of Rocket Pharmaceuticals worth $3,112,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Nisa Investment Advisors LLC grew its position in shares of Rocket Pharmaceuticals by 31.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 764 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Rocket Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 582 shares during the period. Values First Advisors Inc. bought a new stake in Rocket Pharmaceuticals during the 3rd quarter valued at approximately $108,000. SG Americas Securities LLC acquired a new position in shares of Rocket Pharmaceuticals during the third quarter worth approximately $113,000. Finally, Dana Investment Advisors Inc. boosted its position in shares of Rocket Pharmaceuticals by 4.4% in the second quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 586 shares during the period. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RCKT has been the topic of several research reports. Chardan Capital restated a “buy” rating and set a $62.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, August 6th. JPMorgan Chase & Co. lifted their price objective on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Scotiabank began coverage on Rocket Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 target price for the company. Canaccord Genuity Group reissued a “buy” rating and issued a $38.00 price target on shares of Rocket Pharmaceuticals in a report on Monday, September 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Rocket Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $51.75.

Rocket Pharmaceuticals Stock Down 0.9 %

Shares of Rocket Pharmaceuticals stock opened at $16.82 on Tuesday. The business has a fifty day simple moving average of $18.21 and a 200 day simple moving average of $20.62. The stock has a market cap of $1.53 billion, a PE ratio of -6.09 and a beta of 1.09. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.05. Rocket Pharmaceuticals, Inc. has a 12 month low of $15.98 and a 12 month high of $32.53.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.02). During the same quarter last year, the business posted ($0.82) EPS. Research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.98 EPS for the current year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.